Blinatumomab

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

High-risk Diffuse Large B-cell Lymphoma

Conditions

High-risk Diffuse Large B-cell Lymphoma

Trial Timeline

May 23, 2018 → Sep 30, 2019

NCT ID

NCT03298412

About Blinatumomab

Blinatumomab is a phase 2 stage product being developed by Amgen for High-risk Diffuse Large B-cell Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03298412. Target conditions include High-risk Diffuse Large B-cell Lymphoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02187354	Pre-clinical	Completed	—	—	Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
NCT07192237	Phase 2	Recruiting	Feb 27, 2026	Oct 12, 2032	Phase 2 Study
NCT07134088	Phase 1/2	Recruiting	Dec 8, 2025	Jun 18, 2030	Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
NCT06649006	Phase 1	Completed	Jan 8, 2025	Dec 4, 2025	B-precursor Acute Lymphoblastic Leukemia
NCT06054113	Phase 2	Active	Jul 23, 2024	Oct 14, 2027	B Precursor Acute Lymphoblastic Leukemia
NCT04448834	Phase 2	Withdrawn	Jan 1, 2022	Jun 1, 2023	B-cell Acute Lymphoblastic Leukemia
NCT04506086	Approved	Terminated	Aug 26, 2021	Sep 16, 2024	B-precursor Acute Lymphoblastic Leukemia
NCT04746209	Phase 2	Recruiting	Feb 1, 2021	Dec 31, 2029	B-cell Acute Lymphoblastic Leukemia
NCT04521231	Phase 1/2	Recruiting	Jan 4, 2021	May 25, 2029	B Cell Precursor Acute Lymphoblastic Leukemia
NCT04556084	Phase 2	Terminated	Jan 1, 2021	Oct 1, 2022	B-cell Acute Lymphoblastic Leukemia
NCT04785547	Phase 2	Terminated	Dec 17, 2020	Jan 22, 2022	ALL, Childhood
NCT04044560	Phase 2	Terminated	Sep 8, 2020	Feb 2, 2022	B-cell Adult Acute Lymphoblastic Leukemia
NCT03751709	Phase 1	Completed	Feb 14, 2020	Nov 12, 2024	B-Cell Acute Lymphoblastic Leukaemia
NCT03298412	Phase 2	Terminated	May 23, 2018	Sep 30, 2019	High-risk Diffuse Large B-cell Lymphoma
NCT02961881	Phase 1	Completed	Sep 18, 2017	Sep 2, 2021	Non-Hodgkin's Lymphoma
NCT02910063	Phase 2/3	Completed	Jan 23, 2017	Mar 12, 2020	B-Cell Non Hodgkin Lymphoma
NCT02807883	Phase 2	Completed	Aug 1, 2016	Feb 1, 2022	Acute Lymphoblastic Leukemia
NCT02811679	Phase 2	Terminated	Aug 1, 2016	Dec 1, 2023	Non-Hodgkin Lymphoma
NCT02412306	Phase 1/2	Completed	Jun 4, 2015	Jul 4, 2019	Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia
NCT02000427	Phase 2	Completed	Jan 3, 2014	Jan 6, 2017	Relapsed/Refractory Philadelphia Positive B-precursor ALL

Competing Products

13 competing products in High-risk Diffuse Large B-cell Lymphoma

See all competitors

Product	Company	Stage	Hype Score
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II	GT Biopharma	Phase 1/2	33
SHR3680 + Placebo	Jiangsu Hengrui Medicine	Phase 3	77
DAPA/MET XR + DAPA + MET XR	AstraZeneca	Phase 3	77
Pembrolizumab + BCG	Merck	Phase 3	77
Blinatumomab + Investigator's Choice Chemotherapy + Dexamethasone	Amgen	Phase 2	51
Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Etoposide + Rituximab + Doxorubicin + Vincristine + Prednisone	Gilead Sciences	Phase 3	76
Darolutamide + ADT	Bayer	Phase 2	49
Esmolol	Baxter	Phase 3	74
N-803 (IL-15 Superagonist) + ETBX-071 (PSA-based Oncolytic Virus) + M-CENK (Activated NK Cells)	ImmunityBio	Phase 2	49
N-803 + ETBX-071 + M-CENK	ImmunityBio	Phase 2	49
Cretostimogene Grenadenorepvec	CG Oncology	Phase 2	49
RP2 Injection	Replimune	Phase 2	44
R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7	PDS Biotechnology	Phase 1	25

Other Products from Amgen